PRAC meeting highlights 5-8 February 2024

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines.

The current PRAC highlights from the February 2024 meeting provides a reminder on the risk of serious adverse reactions when Paxlovid is taken together with certain immunosuppressants.